| For: | Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i23/2457.htm |
| Number | Citing Articles |
| 1 |
Lorenzo Bertani, Laura Baglietto, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Eleonora Albano, Linda Ceccarelli, Maria Gloria Mumolo, Carolina Pellegrini, Ersilia Lucenteforte, Nicola de Bortoli, Massimo Bellini, Santino Marchi, Corrado Blandizzi, Francesco Costa. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. British Journal of Clinical Pharmacology 2020; 86(7) doi: 10.1111/bcp.14235
|
| 2 |
Ahmed Aljabri, Ghareb M. Soliman, Yasmin N. Ramadan, Mohammed A. Medhat, Helal F. Hetta. Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01558-6
|
| 3 |
Laith Alrubaiy, Louise Christine Pitsillides, Thomas O’Connor, Matilda Woodhill, Harry Higgins, Thaer Khaleel Swaid, Doa’a Alkhader, Zaher Koutoubi. Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE). Gastrointestinal Disorders 2024; 6(3) doi: 10.3390/gidisord6030043
|
| 4 |
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, Jean-Frederic Colombel, Jyoti Chauhan, Marion Ehrich, Nicholas Farinola, Josep Bassaganya-Riera. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflammatory Bowel Diseases 2019; doi: 10.1093/ibd/izz094
|
| 5 |
Mária Kolesárová, Anita Vassová, Dana Marcinčáková, Ján Kyselovič, Andrea Gažová. Analysis of Crohn´s disease pharmacotherapy in the child and adult population. Klinická farmakologie a farmacie 2023; 37(2) doi: 10.36290/far.2023.009
|
| 6 |
L.V. Tarasova, E.I. Busalaeva, Yu.V. Tsyganova, N.V. Zhudtlina, I.D. Matysyakevich. Vedolizumab in ulcerative colitis: clinical case. Dokazatel'naya gastroenterologiya 2020; 9(3) doi: 10.17116/dokgastro2020903177
|
| 7 |
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone. Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intestinal Research 2022; 20(1) doi: 10.5217/ir.2021.00037
|
| 8 |
Lorenzo Bertani. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. Journal of Clinical Medicine 2022; 11(18) doi: 10.3390/jcm11185267
|
| 9 |
David M. Faleck, Michael Dougan, Monique Tello, Joseph E. Grossman, Alan C. Moss, Michael A. Postow. Accelerating the Evolution of Immune-Related Enterocolitis Management. Journal of Clinical Oncology 2023; 41(17) doi: 10.1200/JCO.22.02914
|
| 10 |
Tugrul Purnak, Atilla Ertan. Optimal Management of Patients with Moderate-to-Severe Inflammatory Bowel Disease. Journal of Clinical Medicine 2024; 13(23) doi: 10.3390/jcm13237026
|
| 11 |
Kevin Groudan, Kamesh Gupta, Rohit Singhania. Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient. Cureus 2021; doi: 10.7759/cureus.12582
|
| 12 |
Ralley E. Prentice, Clarissa Rentsch, Aysha H. Al‐Ani, Eva Zhang, Douglas Johnson, John Halliday, Robert Bryant, Jacob Begun, Mark G. Ward, Peter J. Lewindon, Susan J. Connor, Simon Ghaly, Britt Christensen. SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease. GastroHep 2021; 3(4) doi: 10.1002/ygh2.473
|
| 13 |
Aleksandra Sokic-Milutinovic, Tomica Milosavljevic. Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy. Digestive Diseases 2024; 42(4) doi: 10.1159/000535647
|
| 14 |
Rita Lauro, Federica Mannino, Natasha Irrera, Francesco Squadrito, Domenica Altavilla, Giovanni Squadrito, Giovanni Pallio, Alessandra Bitto. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021; 9(12) doi: 10.3390/biomedicines9121748
|
| 15 |
Saqr Alsakarneh, June Tome, Francis A. Farraye, Darrell S. Pardi. Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis—A Population‐Based Study. Alimentary Pharmacology & Therapeutics 2026; 63(3) doi: 10.1111/apt.70404
|
| 16 |
Virginia Solitano, Gionata Fiorino, Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese. Thrombosis in IBD in the Era of JAK Inhibition. Current Drug Targets 2020; 22(1) doi: 10.2174/1389450121666200902164240
|
| 17 |
Renu Bhandari, Opemipo D Ogeyingbo, Roaa Kareem, Mallika Gyawali, Nanditha Venkatesan, Rowan Ahmed, Rinky A Botleroo, Abeer O Elshaikh. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review. Cureus 2021; doi: 10.7759/cureus.17729
|
| 18 |
Thomas Wilke, Antje Groth, Gráinne H. Long, Amanda R. Tatro, Diana Sun. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany. Clinical Therapeutics 2020; 42(1) doi: 10.1016/j.clinthera.2019.11.012
|
| 19 |
Hiroshi Nakase. 4) Treatment of Inflammatory Bowel Disease Based on the Pathophysiology-for the Present and the Future-. Nihon Naika Gakkai Zasshi 2020; 109(9) doi: 10.2169/naika.109.1759
|
| 20 |
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Martin Hoffstadt, Thomas Krause, Axel Schweitzer, Elisabeth Schnoy, Raja Atreya, Niels Teich, Leo Trentmann, Robert Ehehalt, Petra Hartmann, Stefan Schreiber. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. Inflammatory Bowel Diseases 2024; 30(5) doi: 10.1093/ibd/izad138
|
| 21 |
Karma Yeshi, Roland Ruscher, Luke Hunter, Norelle L. Daly, Alex Loukas, Phurpa Wangchuk. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. Journal of Clinical Medicine 2020; 9(5) doi: 10.3390/jcm9051273
|
| 22 |
Afsar U. Ahmed. Targeting Integrins in Immunity: Precision Matters for Therapeutic Interventions. Frontiers in Bioscience-Landmark 2026; 31(7) doi: 10.31083/FBL47669
|
| 23 |
Fabio Salvatore Macaluso, Ambrogio Orlando, Claudio Papi, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Andrea Buda, Emma Calabrese, Federica Furfaro, Salvatore Leone, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Enrica Previtali, Mariabeatrice Principi, Sara Renna, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Simone Saibeni, Gianluca Matteo Sampietro, Edoardo Savarino, Anna Testa, Angela Variola, Angelo Viscido, Sandro Ardizzone, Livia Biancone, Maria Cappello, Fabiana Castiglione, Rachele Ciccocioppo, Michele Comberlato, Francesco Costa, Renata D'Incà, Silvio Danese, Antonio Di Sabatino, Walter Fries, Paolo Gionchetti, Giovanni Latella, Francesco Manguso, Mauro Mastronardi, Gianmichele Meucci, Monica Milla, Maria Lia Scribano, Maurizio Vecchi. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease 2022; 54(4) doi: 10.1016/j.dld.2022.01.127
|
| 24 |
Weili Xu, Tessa Bergsbaken, Karen L. Edelblum. The multifunctional nature of CD103 (αEβ7 integrin) signaling in tissue-resident lymphocytes. American Journal of Physiology-Cell Physiology 2022; 323(4) doi: 10.1152/ajpcell.00338.2022
|
| 25 |
Giorgos Bamias, Georgios Kokkotis, Michalis Gizis, Christina Kapizioni, Konstantinos Karmiris, Evgenia Koureta, Nikolaos Kyriakos, Georgios Leonidakis, Konstantinos Makris, Panagiotis Markopoulos, Georgios Michalopoulos, Spyridon Michopoulos, Ioannis Papaconstantinou, Dimitrios Polymeros, Spyros I. Siakavellas, Konstantinos Triantafyllou, Eftychia Tsironi, Emmanouela Tsoukali, Maria Tzouvala, Nikos Viazis, Vassileios Xourafas, Eirini Zacharopoulou, Evanthia Zampeli, Konstantinos Zografos, George Papatheodoridis, Gerasimos Mantzaris. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Digestive Diseases and Sciences 2022; 67(3) doi: 10.1007/s10620-021-06907-5
|
| 26 |
Andreja Ocepek, Nikolaus Molinari, Petra Maček, Jan Zmazek, Sara Nikolić. Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina 2026; 62(4) doi: 10.3390/medicina62040722
|
| 27 |
Sophia Ponciano de Souza, Paulo Gabriel Marques Leite, Ana Júlia Oliveira Silva, Camila Belfort Piantino Faria. O USO DO VEDOLIZUMBABE NO TRATAMENTO DA DOENÇA DE CRONH: UMA REVISÃO INTEGRATIVA. REVISTA FOCO 2024; 17(7) doi: 10.54751/revistafoco.v17n7-017
|
| 28 |
Yimin Ding, Qian Cao, Wenjuan Yang, Junjie Xu, Peng Xiao. Macrophage: Hidden Criminal in Therapy Resistance. Journal of Innate Immunity 2024; 16(1) doi: 10.1159/000538212
|
| 29 |
Vishal Sharma, Kayal Vizhi Nagarajan, Parna Pathak, Rishabh Agarwal, Nikhil Patil, Kim Vaiphei, Naresh Bhat. Gastrointestinal Tuberculosis after Vedolizumab Treatment in Inflammatory Bowel Disease: Brief Report. Journal of Gastrointestinal Infections 2024; 14(02) doi: 10.1055/s-0045-1802668
|
| 30 |
Anna Sebestyén, Titanilla Dankó, Dániel Sztankovics, Dorottya Moldvai, Ildikó Krencz, Regina Raffay, Gábor Petővári. The Extracellular Matrix and the Tumor Microenvironment. Biology of Extracellular Matrix 2022; 11 doi: 10.1007/978-3-030-99708-3_13
|
| 31 |
Hiroshi Nakase. Treatment of inflammatory bowel disease from the immunological perspective. Immunological Medicine 2020; 43(2) doi: 10.1080/25785826.2020.1751934
|
| 32 |
Georgia Kyriakou, Maria Gkermpesi, Konstantinos Thomopoulos, Markos Marangos, Sophia Georgiou. Metastatic vulvar Crohn’s disease preceding intestinal manifestations: a case report and short review. Acta Dermatovenerologica Alpina Pannonica et Adriatica 2019; 28(3) doi: 10.15570/actaapa.2019.32
|
| 33 |
. 2020; doi: 10.70675/40b56131z5a56z4dd4za92bzfd9b187295f2
|
| 34 |
C. Abreu, R. Filipe, S. Lopes, A. Sarmento. Varicella under vedolizumab: Should we wait for the disease or propose the vaccine?. Journal of Clinical Virology 2020; 126 doi: 10.1016/j.jcv.2020.104333
|
| 35 |
Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Stefanie Howaldt, Wolfgang Mohl, Philipp Efken, Robert Ehehalt, Matthias Kahl, Thomas Krause, Leo Trentmann, Andreas Lügering, Elisabeth Schnoy, Christoph Jochum, Petra Hartmann, Stefan Schreiber. Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study. Journal of Crohn's and Colitis 2025; 19(5) doi: 10.1093/ecco-jcc/jjaf052
|
| 36 |
Hiroshi Nakase. The Leading Edge of the Treatment of Inflammatory Bowel Disease. Nihon Naika Gakkai Zasshi 2020; 109(6) doi: 10.2169/naika.109.1145
|
| 37 |
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine, Frank M Ruemmele. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 2021; 15(2) doi: 10.1093/ecco-jcc/jjaa161
|
| 38 |
Tommaso Innocenti, Jenny Roselli, Erica N. Lynch, Pasquale Apolito, Laura Parisio, Siro Bagnoli, Giuseppe Macrì, Francesca Rogai, Mirko Tarocchi, Stefano Milani, Andrea Galli, Monica Milla, Gabriele Dragoni. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 2021; 33(1S) doi: 10.1097/MEG.0000000000002166
|
| 39 |
Kathryn Gazelakis, Isabel Chu, Catherine Martin, Miles P. Sparrow. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal 2024; 54(1) doi: 10.1111/imj.16105
|
| 40 |
Tamar Getter, Raanan Margalit, Shirin Kahremany, Laura Levy, Eliav Blum, Netaly Khazanov, Nimrod Y. Keshet-Levy, Tigist Y. Tamir, M. Ben Major, Ron Lahav, Sofia Zilber, Hanoch Senderowitz, Paul Bradfield, Beat A. Imhof, Evgenia Alpert, Arie Gruzman. Novel inhibitors of leukocyte transendothelial migration. Bioorganic Chemistry 2019; 92 doi: 10.1016/j.bioorg.2019.103250
|
| 41 |
Chathyan Pararasa, Na Zhang, Thomas J. Tull, Ming H. A. Chong, Jacqueline H. Y. Siu, William Guesdon, Konstantia Maria Chavele, Jeremy D. Sanderson, Louise Langmead, Klaartje Kok, Jo Spencer, Anna Vossenkamper. Reduced CD27−IgD− B Cells in Blood and Raised CD27−IgD− B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00361
|
| 42 |
Beatriz Chaves, Geraldo R. Sartori, Disraeli C. A. Vasconcelos, Wilson Savino, Ernesto R. Caffarena, Vinícius Cotta-de-Almeida, João H. M. da Silva. Guidelines To Predict Binding Poses of Antibody–Integrin
Complexes. ACS Omega 2020; 5(27) doi: 10.1021/acsomega.0c00226
|
| 43 |
Caroline Di Jiang, Tim Raine. IBD considerations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease 2020; 12 doi: 10.1177/1759720X20939410
|
| 44 |
Ana Avedillo-Salas, Sara Corral-Cativiela, Ana Fanlo-Villacampa, Jorge Vicente-Romero. The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review. Pharmaceuticals 2023; 16(11) doi: 10.3390/ph16111581
|
| 45 |
Zhaobei Cai, Shu Wang, Jiannan Li. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.765474
|
| 46 |
Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun. Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research 2025; 23(4) doi: 10.5217/ir.2024.00174
|
| 47 |
Gloria Krajnc, Lara Metlika, Uroš Potočnik, Boris Gole. Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease. BIOCELL 2025; 49(6) doi: 10.32604/biocell.2025.063486
|
| 48 |
Marco De Zuani, Chiara Dal Secco, Barbara Frossi. Mast cells at the crossroads of microbiota and IBD. European Journal of Immunology 2018; 48(12) doi: 10.1002/eji.201847504
|
| 49 |
Thomas X. Lu, Russell D. Cohen. Maneuvering Clinical Pathways for Crohn’s Disease. Current Gastroenterology Reports 2019; 21(5) doi: 10.1007/s11894-019-0687-4
|
| 50 |
Yunwei Wang, Jennifer Wang, Joel Pekow, Sushila Dalal, Russell D Cohen, Jacob Ollech, Amanda Israel, Benjamin D Shogan, Dejan Micic, Lisa Cannon, Konstantin Umanskiy, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist‐maintained clinical remission. Journal of Gastroenterology and Hepatology 2019; 34(12) doi: 10.1111/jgh.14751
|
| 51 |
Ugo Cucinotta, Valeria Dipasquale, Stefano Costa, Salvatore Pellegrino, Vincenzo Ramistella, Claudio Romano. Vedolizumab‐associated pulmonary manifestations in children with ulcerative colitis. Journal of Clinical Pharmacy and Therapeutics 2022; 47(2) doi: 10.1111/jcpt.13494
|
| 52 |
Thomas Klag, Jan Wehkamp, Eduard Stange. Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED. Gastro-News 2019; 6(1) doi: 10.1007/s15036-019-0482-y
|
| 53 |
Richard Vollenberg, Phil-Robin Tepasse, Joachim Ewald Kühn, Marc Hennies, Markus Strauss, Florian Rennebaum, Tina Schomacher, Göran Boeckel, Eva Lorentzen, Arne Bokemeyer, Tobias Max Nowacki. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022; 10(1) doi: 10.3390/biomedicines10010171
|
| 54 |
Gerhard Rogler. Mechanism of action of vedolizumab: do we really understand it?. Gut 2019; 68(1) doi: 10.1136/gutjnl-2018-316777
|
| 55 |
Daxin Guo, Ke Jiang, Jiaze Hong, Mengting Zhang, Yetan Shi, Bin Zhou. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. International Journal of Colorectal Disease 2021; 36(10) doi: 10.1007/s00384-021-04017-2
|
| 56 |
Victor Avram, Shweta Yadav, Pranav Sahasrabudhe, Dan Chang, Jing Wang. IBDTransDB: a manually curated transcriptomic database for inflammatory bowel disease. Database 2024; 2024 doi: 10.1093/database/baae026
|
| 57 |
Bernd Bokemeyer, Sandra Plachta‐Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Thomas Krause, Martin Hoffstadt, Robert Ehehalt, Leo Trentmann, Axel Schweitzer, Petra Jessen, Petra Hartmann, Stefan Schreiber. Real‐world effectiveness of vedolizumab compared toanti‐TNFagents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observationalVEDOIBD‐study. Alimentary Pharmacology & Therapeutics 2023; 58(4) doi: 10.1111/apt.17616
|
| 58 |
Shinsuke Otagiri, Keiya Aoyama, Takehiko Katsurada, Takahiro Ito, Atsuo Maemoto, Fumika Orii, Toshifumi Ashida, Masanao Nasuno, Hiroki Tanaka, Katsuyoshi Ando, Mikihiro Fujiya, Yoshihiro Yokoyama, Satoshi Motoya, Hiroshi Nakase. Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn’s Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort. Inflammatory Intestinal Diseases 2026; 11(1) doi: 10.1159/000552221
|
| 59 |
Zahra Izadiyan, Roshafima Rasit Ali, Thomas J. Webster, Zahra Maghareh Esfahan, Kamyar Shameli. Antigen–antibody interactions in precision medicine: Molecular mechanisms, targeted drug delivery, and nanomedicine applications. Letters in Drug Design & Discovery 2026; 23(5) doi: 10.1016/j.lddd.2026.100478
|
| 60 |
Martina Palatella, Sabrina Wagner, Dirk H. Busch, Jochen Huehn. The Gut Microbiome in Health and Disease. 2026; doi: 10.1007/978-3-032-26410-7_9
|
| 61 |
S. Hopkin, J.M. Lord, M. Chimen. Dysregulation of leukocyte trafficking in ageing: Causal factors and possible corrective therapies. Pharmacological Research 2021; 163 doi: 10.1016/j.phrs.2020.105323
|
| 62 |
Richard Vollenberg, Phil-Robin Tepasse, Eva Lorentzen, Tobias Max Nowacki. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. Journal of Personalized Medicine 2022; 12(5) doi: 10.3390/jpm12050694
|
| 63 |
Molly Harte, John Macken, Lifong Zou, Farida Fortune. Case report: Vedolizumab in Oral Crohn’s disease: the downsides of a gut-specific therapy for a multi-site disease. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1485394
|
| 64 |
Andreia S. Barros, Rute Nunes, Bruno Sarmento. Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles. Journal of Controlled Release 2026; 389 doi: 10.1016/j.jconrel.2025.114466
|
| 65 |
Yousef R Badran, Fangwen Zou, Sienna M Durbin, Barbara E Dutra, Hamzah Abu-Sbeih, Anusha S Thomas, Mehmet Altan, John A Thompson, Wei Qiao, Donna E Leet, Po-Ying Lai, Nora K Horick, Michael A Postow, David M Faleck, Yinghong Wang, Michael Dougan. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer 2023; 11(6) doi: 10.1136/jitc-2023-007195
|
| 66 |
Evripidis D. Rizos, Elvira-Markela Antonogiannaki, Alexandros Chatzidakis, Maria Kallieri, Zoi Tsilogianni, Effrosyni D. Manali, Nikolaos Economopoulos, Konstantinos Triantafyllou, Spyros A. Papiris, Dimitrios Polymeros. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis. European Journal of Gastroenterology & Hepatology 2021; 33(1S) doi: 10.1097/MEG.0000000000002197
|
| 67 |
Stanislav Georgiev, Lyuboslava Pampulova, Philip Abedinov, Rumen Iliev, Emil Hadzhiev, Dimitar Petkov. How many risk factors are too many: massive pulmonary embolism in a patient with ulcerative colitis and steroid-induced vertebral fractures: a case report. Pharmacia 2026; 73 doi: 10.3897/pharmacia.73.e208292
|
| 68 |
Lorenzo Bertani, Gian Paolo Caviglia, Luca Antonioli, Rinaldo Pellicano, Sharmila Fagoonee, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Corrado Blandizzi, Francesco Costa, Davide Giuseppe Ribaldone. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine 2020; 9(5) doi: 10.3390/jcm9051323
|
| 69 |
. 2023; doi: 10.70675/bc2a7731zeb07z4040zbfcez56e1a8040338
|
| 70 |
Amandip Kaur, Paraskevi Goggolidou. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. Journal of Inflammation 2020; 17(1) doi: 10.1186/s12950-020-00246-4
|
| 71 |
Cath Stansfield. Vedolizumab (Entyvio) in Crohn's disease. Gastrointestinal Nursing 2021; 19(6) doi: 10.12968/gasn.2021.19.6.20
|
| 72 |
Blake Smith, Haylie Smith, Matthew Machini. Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review. Cureus 2024; doi: 10.7759/cureus.65357
|
| 73 |
Ida Schoultz, Åsa V. Keita. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier Function. Cells 2019; 8(2) doi: 10.3390/cells8020193
|
| 74 |
Thinagary Jegathesan, Syaratul Dalina Yusoff, Nor Asyikin Mohd Tahir. Genetic polymorphism associated with non-response to therapy in inflammatory bowel disease patients: a review. Pharmacogenomics 2025; 26(7-9) doi: 10.1080/14622416.2025.2547561
|
| 75 |
Lorenzo Bertani, Corrado Blandizzi, Maria Gloria Mumolo, Linda Ceccarelli, Eleonora Albano, Gherardo Tapete, Giovanni Baiano Svizzero, Federico Zanzi, Francesca Coppini, Nicola de Bortoli, Massimo Bellini, Riccardo Morganti, Santino Marchi, Francesco Costa. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clinical and Translational Gastroenterology 2020; 11(5) doi: 10.14309/ctg.0000000000000174
|
| 76 |
Fabiana Zingone, Brigida Barberio, Federico Compostella, Giulia Girardin, Renata D’Incà, Carla Marinelli, Ilaria Marsilio, Greta Lorenzon, Edoardo Vincenzo Savarino. Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820936536
|
| 77 |
George Hajishengallis, Triantafyllos Chavakis. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nature Reviews Immunology 2021; 21(7) doi: 10.1038/s41577-020-00488-6
|
| 78 |
Mario Fernández-Ruiz, José María Aguado. Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis. Infectious Disease Clinics of North America 2020; 34(2) doi: 10.1016/j.idc.2020.02.002
|
| 79 |
Luigi Santacroce, Eleonora Lo Muzio, Lucrezia Bottalico, Francesca Spirito, Ioannis Alexandros Charitos, Pier Carmine Passarelli, Emilio Jirillo. Subversion of the Oral Microbiota and Induction of Immune-Mediated Systemic
Inflammation with Special Reference to Periodontitis: Current
Knowledge and Perspectives. Endocrine, Metabolic & Immune Disorders - Drug Targets 2023; 23(4) doi: 10.2174/1871530322666220629101357
|
| 80 |
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber, Silvio Danese. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2021; 27(1) doi: 10.1093/ibd/izaa078
|
| 81 |
Sebastián Eduardo Ibáñez Vodnizza, María Paz Poblete De La Fuente, Elisa Catalina Parra Cancino. Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease. Rheumatic Disease Clinics of North America 2020; 46(2) doi: 10.1016/j.rdc.2020.01.004
|
| 82 |
Amanda Nash, Samira Aghlara-Fotovat, Andrea Hernandez, Christopher Scull, Omid Veiseh. Clinical translation of immunomodulatory therapeutics. Advanced Drug Delivery Reviews 2021; 176 doi: 10.1016/j.addr.2021.113896
|